Baker Avenue Asset Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Baker Avenue Asset Management’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-10,000	Closed	-$82K	–	258
2021 Q1	$82K	Hold	10,000	–	–	0.01%	240
2020 Q4	$68K	Hold	10,000	–	–	﹤0.01%	236
2020 Q3	$111K	Hold	10,000	–	–	0.01%	217
2020 Q2	$63K	Hold	10,000	–	–	0.01%	233
2020 Q1	$18K	Buy	+10,000	New	+$28.8K	﹤0.01%	195
2019 Q4	–	Sell	-10,000	Closed	-$21K	–	275
2019 Q3	$21K	Hold	10,000	–	–	﹤0.01%	238
2019 Q2	$26K	Hold	10,000	–	–	﹤0.01%	235
2019 Q1	$47K	Buy	+10,000	New	+$26.2K	﹤0.01%	242

Other funds holding SRNE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Baker Avenue Asset Management's SRNE Position: Q2 2021 in Review

Baker Avenue Asset Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2021, closing a stake of 10,000 shares — an estimated $82K sold.

Baker Avenue Asset Management first reported a position in SRNE in Q1 2019 and held it in 8 quarters. The position peaked at $111K in Q3 2020. 212 funds tracked by Wall St. Rank hold SRNE as of Q2 2021.

Baker Avenue Asset Management reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
Baker Avenue Asset Management sold 10,000 Sorrento Therapeutics, Inc. shares in Q2 2021, an estimated $82K.
Baker Avenue Asset Management first reported a position in Sorrento Therapeutics, Inc. in Q1 2019 and held it in 8 quarters.
Baker Avenue Asset Management's Sorrento Therapeutics, Inc. position peaked at $111K in Q3 2020.
212 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2021.

Based on Baker Avenue Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.